Vitality Watch

⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.

Mentioned 1× · first seen 28-sep-2026 · last seen 28-sep-2026

Hepassocin (HPS) as an Age-Declining Hepatokine

Current understanding

Hepassocin (HPS/FGL1) is a liver-secreted hepatokine that declines with age in mice and shows correlative decline in humans; preclinical work positions it as an upstream restraint on hepatocyte senescence and a permissive signal for liver regeneration by activating AMPK through an ANXA2–ERK–p90RSK–LKB1 phosphorylation cascade [animal-model]. Exogenous HPS or the AMPK activator AICAR rescues regeneration and senescence phenotypes in aged mice [animal-model], with only correlative human data so far.

Evidence log

Open questions

Related

Contributing findings

pubmed preclinical
Hepassocin prevents age-related liver senescence and facilitates liver regeneration by activating AMPK.
15-sep-2026 novelty 3 per-area 3 introduces

build build 880 · 2bcef25 · 2026-11-18